16-9500-38

antibody from Invitrogen Antibodies

Targeting: TIGIT DKFZp667A205, FLJ39873, VSIG9, VSTM3

Provider product page for 16-9500-38

Immunohistochemistry

Flow cytometry

Other assay

Antibody data

Antibody Data
Antigen structure
References [22]
Comments [0]
Validations
Other assay [27]

Submit

Product number: 16-9500-38 - Provider product page
Provider: Invitrogen Antibodies
Product name: TIGIT Monoclonal Antibody (MBSA43), Functional Grade, eBioscience™
Antibody type: Monoclonal
Antigen: Other
Description: Description: The MBSA43 monoclonal antibody reacts with human T cell immunoreceptor with Ig and ITIM domains (TIGIT), which is also known as VSTM3 or WUCAM. This 26 kDa protein is a member of the poliovirus receptor (PVR) family. The expression of TIGIT has been reported on NK cells, regulatory T cells, follicular T helper cells, memory CD4+ T cells, and CD8+ T cells, but it is not expressed on B cells or naive CD4+ T cells. TIGIT may be upregulated on naive CD4+ T cells upon activation. TIGIT can interact with certain members of the PVR and PVR-like families, including CD155, and also mediates the interaction of NK and T cells with antigen presenting cells, fibroblasts, and endothelial cells that express PVR and PVR-like proteins. MBSA43 is reported to crossreact with Rhesus macaque. Applications Reported: This MBSA43 antibody has been reported for use in flow cytometric analysis. In a functional assay, MBSA43 enhances IFN gamma secretion following TCR activation. Applications Tested: This MBSA43 antibody has been tested by flow cytometric analysis. This can be used at less than or equal to 0.25 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Storage and handling: Use in a sterile environment. Filtration: 0.2 µm post-manufacturing filtered. Purity: Greater than 90%, as determined by SDS-PAGE. Endotoxin Level: Less than 0.001 ng/µg antibody, as determined by LAL assay. Aggregation: Less than 10%, as determined by HPLC.
Reactivity: Human
Host: Mouse
Isotype: IgG
Antibody clone number: MBSA43
Vial size: 5 mg
Concentration: 1 mg/mL
Storage: 4° C

TIGIT protein structure - 16-9500-38 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig 4 TIGIT expressing CD8 + T cells have impaired cytokine responses. Representative flow cytometry plots gated on CD8 + T cells showing (A) TIGIT or (C) PD-1 expression against Ki-67 from a chronically HIV-infected individual. Compiled data of Ki-67 + CD8 + T cell frequency (%) separated into (B) TIGIT + and TIGIT - or (D) PD-1 + and PD-1 - ( n = 20). P values were calculated by Wilcoxon matched-pairs signed ranked test. Ex vivo PBMCs from chronically HIV-infected individuals were stimulated with HIV Gag peptide pool and assessed for cytokine production. (E) Representative flow cytometry plots gated on CD8 + T cells showing TIGIT expression and either IFN-gamma, IL-2, or TNF-alpha content after no stimulation, stimulation with an HIV-1 Gag peptide pool, or a positive control stimulation with anti-CD3 + anti-CD28 Dynabeads. (F) Compiled data of IFN-gamma, IL-2, or TNF-alpha CD8 + T cell frequency (%) from TIGIT + or TIGIT - CD8 + T cell compartments after HIV-1 Gag peptide pool stimulation (sample group includes; AS n = 4, EC n = 3, NC n = 3). P values were calculated by Wilcoxon matched-pairs signed ranked test. (G) Compiled data of TIGIT and PD-1 expression on HIV-1 Gag responding cells (sample group includes; AS n = 4, EC n = 3, NC n = 3). P values were calculated with repeated-measures one-way ANOVA, followed by Tukey's multiple comparisons test (*p < 0.05; **p < 0.01; ***p < 0.001). (H) Representative flow cytometry plots of intracellular perforin and granzyme B fr

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 2 Fig. The expression of gammadelta T cells and their co-stimulatory molecules T cell immunoglobulin and ITIM domain (TIGIT), programmed cell death 1 (PD-1), B and T lymphocyte attenuator (BTLA) and inducible co-stimulator (ICOS) as measured by flow cytometry and FlowJo software. (a) gammadelta T cell receptor (CD3 + gammadelta TCR + ) gating strategy in peripheral blood. (b) gammadelta T cell (CD45 + CD3 + gammadelta TCR + ) gating strategy in decidual tissue.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 3 Fig. The proportion of gammadelta T cells and the expression of their co-stimulatory molecules T cell immunoglobulin and ITIM domain (TIGIT), inducible co-stimulator (ICOS), B and T lymphocyte attenuator (BTLA) and programmed cell death 1 (PD-1) as determined by flow cytometry. The data are expressed as the mean +- standard error of the mean (s.e.m.). (a-e) Peripheral blood; normal pregnant (NP) group, n = 30; unexplained recurrent spontaneous abortion (URSA) group, n = 32; n.s. = not significant. (f-j) Decidual tissue; NP group, n = 11; URSA group, n = 15.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure1. Co-expression of TIGIT and TIM-3 is upregulated on NK cells in HBV-HCC patients. a-b The Proportion of total NK cells and NK cell subsets(CD56 bright NK cells,CD56 dim NK cells, and CD56 - NK cells) from HBV-HCC (n = 133), compared with HDs (n = 32), CHB (n = 23),and HBV-LC patients (n = 25) by flow cytometry analysis. c-d The expression of TIGIT (c) and TIM-3 (d) on total NK cells and NK cell subsets(CD56 bright NK cells,CD56 dim NK cells, and CD56 - NK cells) from HBV-HCC, HDs, CHB and HBV-LC patients. P values were calculated by using the Kruskal-Wallis nonparametric H test. * P < .05, ** P < .01, *** P < .001, **** P < .0001

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure2. The co-expression of TIGIT and TIM-3 is elevated on NK cells of progression patients with HBV-HCC. a-b Percentages of TIGIT + TIM-3 + NK cells on total NK cells and NK cell subsets(CD56 bright NK cells,CD56 dim NK cells, and CD56 - NK cells) from HBV-HCC, HDs, CHB and HBV-LC patients by flow cytometry analysis. c Correlation analysis of TIGIT and TIM-3 on NK cells from patients with HBV-HCC. d-e Flow-cytometry analyses (d) of TIGIT and TIM-3 were performed on PBMCs collected from HBV-HCC patients. Representative plots (e) display the expression of TIGIT + NK cells, TIM-3 + NK cells and total TIGIT + TIM-3 + NK cells from patients with progression (n = 61) and no progression (n = 72). P values were calculated by using the Kruskal-Wallis nonparametric H test (a-c). P values were obtained by the unpaired t test (d-e). * P < .05, ** P < .01, *** P < .001, **** P < .0001

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 4 Frequency and differentiation status of SARS-CoV-2-specific MHC-I multimer + T cells. PBMC samples ( n = 15) from individuals with SARS-CoV-2 infection ( n = 11) were analyzed by flow cytometry. a Representative flow cytometry plots showing the ex vivo detection of SARS-CoV-2 S 269 multimer + CD8 + T cells in the gate of CD3 + T cells. b Scatter plot showing the relationship between DPSO and the frequency of SARS-CoV-2 S 269 multimer + cells among total CD8 + T cells. Samples from the same patient are connected by solid lines. The expression of CCR7, CD45RA, and CD95 was analyzed in SARS-CoV-2 S 269 multimer + CD8 + T cells. IAV MP 58 multimer + ( n = 5) and CMV pp65 495 multimer + ( n = 6) cells from the PBMCs of healthy donors were also analyzed. Representative flow cytometry plots ( c ) show the proportion of the indicated subsets among multimer + cells, and scatter plots ( d ) show the relationship between DPSO and the proportion of the indicated subsets among SARS-CoV-2 S 269 multimer + cells. Samples from the same patient are connected by solid lines. Summary data showing the proportion of the indicated subsets among IAV multimer + and CMV multimer + cells are also presented ( d ). Horizontal lines represent median. e A representative flow cytometry plot (upper) and summary data (lower) showing the percentage of PD-1 - TIGIT - cells among SARS-CoV-2 S 269 multimer + CD8 + T SCM cells and total SARS-CoV-2 S 269 multimer + CD8 + T cells. Statistical analysis was pe

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 6 Cell-to-cell communications between cancer cells and immune cells. A - F Heatmaps showing numbers of cell-cell interactions across cell types from variant sample origins. G, H NATMI networks showing ligand-receptor pairs among cells in lymph nodes with TNBC ( G ) and non-TNBC ( H ) cells. I Table showing impressive molecules and corresponding ligand-receptor pairs associated with breast cancer metastasis and the respective references. J Immunofluorescence staining of NECTIN2-TIGIT pair in lymph nodes with cancer cells.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3. Representative flow cytometry histograms of the Teffs proliferation rate with the ratio of Tregs to Teffs was 1:1 after addition of double antibodies or anti-PD-1 and anti-TIGIT respectively among the different groups. Treg cells and Teff cells were isolated using magnetic beads and were mixed at the ratio of 1:1. Then, the Teffs proliferation rate was calculated by flow cytometry and analyzed by FlowJo Software.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig 1 Expression of TIGIT on T cells during HIV infection. Cryopreserved PBMCs were thawed and surface phenotyped for TIGIT expression. Representative flow cytometry flow plots showing TIGIT expression on (A) CD8 + or (B) CD4 + T cells compared to fluorescence minus one (FMO) control. Graphs show compiled data of TIGIT expression on (C) CD8 + and (D) CD4 + T cells stratified by disease: HIV-uninfected healthy donors (HD, X; n = 20), acute HIV-infection (AI, open diamond; n = 24), aviremic cART suppressed (AS, open triangles; n = 20), aviremic elite controllers (EC, open squares; n = 20), and chronic HIV viremic non-controllers (NC, open circles; n = 20). P values were calculated using one-way ANOVA, followed by Tukey's multiple comparisons test. Graphs show correlation of total chronic infected (+: AS, EC, and NC; left panel, n = 60) and non-controllers (right panel, n = 20) frequency (%) of (E) TIGIT + CD8 + and (F) TIGIT + CD4 + T cells against clinical CD4 Count (cells/mm 3 ). Graphs show correlation of total chronic infected (+: AS, EC, and NC; left panel, n = 60) and elite controllers (right panel, n = 20) frequency (%) of (G) TIGIT + CD8 + and (H) TIGIT + CD4 + T cells against frequency (%) of T cell activation (CD38 + HLA-DR + ). Graphs show correlation of frequency (%) of (I) TIGIT + CD8 + and (J) TIGIT + CD4 + T cell among aviremic HIV infected ""ART initiators"" with known duration of long-term viral suppression from the SCOPE cohort (L-AS, n = 19, open inverte

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig 2 TIGIT expression on CD8 + terminal effector T cells and HIV-specific CD8 + T cells. Cryopreserved PBMCs were thawed and surface phenotyped for TIGIT expression on CD8 + T cell compartments. (A) Graph shows compiled frequency (%) of TIGIT + CD8 + T cell expression in differentiated compartments stratified by disease status. HIV-uninfected healthy donors (HD, X; n = 20), acute infected (AI, open diamond; n = 24), cART suppressed (AS, open triangle; n = 20), elite controller (EC, open square; n = 20), non-controllers (NC, open circle; n = 20). P values were calculated using one-way ANOVA, followed by Tukey's multiple comparisons test (*p < 0.05; **p < 0.01; ***p < 0.001). PBMCs from HLA-A*02:01 or HLA-B*07:02 HIV chronically infected individuals were stained with matched HLA pentamers presenting HIV-1 and CMV epitopes and anti-TIGIT. (B) Representative flow cytometry plots of pentamer-specific CD8 + T cells using HLA-A*02:01 HIV-1 Gag SLYNTVATL (A2*SL9), HLA-A*02:01 HIV-1 Pol ILKEPVHGV (A2*IV9), HLA-B*07:02 HIV-1 Env IPRRIRQGL (B7*IL9), HLA-B*07:02 HIV-1 Nef TPGPGVRYPL (B7*TL10), and HLA-A*02:01 CMV pp65 NLVPMVATV (A2*NV9) (C) Compiled data of TIGIT expression frequency (%) on pentamer specific CD8 + T cells which was recalculated to 100% (left panel, n = 9) compiled data of TIGIT geometric mean fluorescence intensity (GMFI) on pentamer specific CD8 + T cells (right panel, n = 9).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig 3 HIV-Gag specific CD8 + T cells co-express TIGIT and PD-1 and exhibit a transitional memory phenotype. Cryopreserved PBMCs were thawed and surface phenotyped for TIGIT and PD-1 expression on CD8 + T cells. (A) Representative flow cytometry plots showing TIGIT and PD-1 expression on CD8 + T cells from one HIV-uninfected individual (left panel) and one HIV-infected individual (right panel). (B) Graph shows compiled frequency (%) of co-expressing TIGIT + PD-1 + CD8 + T cells from HIV-uninfected (HD, n = 20), chronic HIV-infected (AS, n = 20; EC, n = 20; NC, n = 20). P values were calculated using one-way ANOVA, followed by Tukey's multiple comparisons test. (C) Graph shows correlation of TIGIT + PD-1 + CD8 + T cells frequency (%) from chronic HIV-infected individuals against CD4 count (cells/mm 3 ) or (D) viral load (copies/ml). Spearman's rho tests were performed for correlations. TIGIT and PD-1 expression on HIV-1 Gag specific CD8 + T cells were evaluated. (E) Representative flow cytometry plot of HIV-specific CD8 + T cells using HLA-A*02:01 HIV-1 Gag SLYNTVATL. (F) Representative flow cytometry plots of TIGIT and PD-1 expression on HIV-1 Gag specific CD8 + T cells (Penta+, left panel; Penta-, right panel). (G) Graphs show compiled frequency (%) of TIGIT and PD-1 on Penta+ (left panel) and Penta- (right panel) (sample group contains; AS n = 11, EC n = 2, NC n = 2). P values were calculated using repeated-measures one-way ANOVA, followed by Tukey's multiple

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig 5 Common gamma-chain cytokines regulate TIGIT expression on CD8 + T cells. Ex vivo PBMCs from chronically HIV-1 infected individuals were stimulated with HIV-1 Gag peptide pool for 12 hours. (A) Representative flow cytometry plot gated on CD8 + T cells showing HIV-1 Gag pentamer with no stimulation (top panel) or HIV-1 Gag stimulation (bottom panel). (B) Representative flow cytometry plot of TIGIT expression on Penta+ and Penta- cells with no stimulation or HIV-1 Gag stimulation. (C) Graph shows compiled frequency (%) of TIGIT on Penta+ cells with no stimulation and HIV-1 Gag stimulation ( n = 9). P values calculated with Wilcoxon matched-pairs signed-rank test. (D) Representative flow cytometry histograms gated on CD8 + T cells overlaid with TIGIT expression frequency before and after cytokine stimulation. Dashed line indicates TIGIT isotype control, shaded histogram indicates TIGIT expression with no stimulation, and the solid line indicates TIGIT expression with cytokine stimulation after six days. Compiled data of TIGIT frequency (%) on CD8 + T cells (E) HIV-Infected participant (open circle; n = 8) (F) HIV-Uninfected participant (X; n = 5). P values were calculated with repeated-measures one-way ANOVA, followed by Tukey's multiple comparisons test.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig 7 Phenotypic and functional assessment of rhTIGIT expression on CD8 + T cells. Cryopreserved rhesus macaque PBMCs were thawed, phenotyped and assessed for function. (A) Graphs show frequency (%) of rhTIGIT + CD8 + T cells from PBMCs (circle), LNs (square), and spleen (triangle) in SIV-uninfected (filled) and SIV-infected (open) animals (SIV-uninfected PBMCs, n = 8; SIV-infected PBMCs, n = 19; SIV-uninfected LNs, n = 8; SIV-infected LNs, n = 22; SIV-uninfected spleen, n = 6; SIV infected spleen, n = 9). P values were calculated with Mann-Whitney U tests. (B) Graphs show correlation of frequency (%) of rhTIGIT + CD8 + T cells in PBMCs (circle) and lymph nodes (square) from SIV-infected animal against plasma SIV viral load log 10 vRNA copy Eq/ml (PBMCs, n = 12; LNs, n = 20). vRNA copy Eq, viral RNA copy equivalents. Spearman''s rho tests were performed for correlations. (C) Representative flow cytometry plots of tetramer stains for Mamu-A*01 restricted SIV-Gag CM9 and SIV-Tat SL8 specific CD8 + T cells from PBMC, LNs, and spleen, in a representative Mamu-A*01 animal with full cART suppression. Compiled data of rhTIGIT expression frequency (%) on tetramer specific CD8 + T cells ( n = 4) from PBMCs (circle), LNs (square), and spleen (triangle) from Mamu-A*01 + macaques with full cART suppression. (D) Representative flow cytometry plots of PBMCs ( n = 12) or lymph nodes ( n = 18) stimulated without or with PMA + Ionomycin. Graphs show frequency (%) of IFN-gamma from CD8 + T cel

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5. TIGIT+ cells display a distinct cytokine profile. (a) Representative dot plots showing intracellular cytokine production after cultivating CLL PBMCs for 24 h with CD3/CD28 activating beads. (b) Cytokine production of TIGIT- or TIGIT+CD4+ T cells in 14 samples. (c) Mean fluorescence intensity ratio (MFIR) of CD155 and CD112 on CD5+CD19+ CLL (top) or CD5+ T cells (bottom). The histograms show representative FACS plots of CLL cells (gated for CD5+CD19+cells) and T cells (CD5+ cells) stained with isotype controls (in gray) and CD112/CD155 specific antibodies (in black). The dot plots show results from n = 14 samples.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Inhibitory receptors have distinct frequencies in T-cell populations from peripheral blood and tumor tissues from eight types of cancer patients. FACS analysis reveals the frequency of PD-1+, Tim-3+, BTLA+, TIGIT+, 2B4+, CD160+, and CTLA-4+ cells in peripheral CD8 T cells (A) , CD8 TILs (B) , peripheral CD4 T cells (C) , and CD4 TILs (D) . T cells were obtained from 131 primary cancer patients, including 38 with breast cancer, 10 with liver cancer, 11 with lung cancer, 9 with esophageal cancer, 14 with gastric cancer, 15 with colorectal cancer, 14 with kidney cancer, and 20 with cervical cancer. The blue dotted line is the mean frequency of PD-1+ cells on each graph. The abovementioned IRs were investigated in three different panels (details are shown in Supplementary Table 2 ). 131 cancer patients were used for the analysis of PD-1, Tim-3, KLRG-1, and 2B4; 74 cancer patients were used for the analysis of BTLA and CD160; and 67 cancer patients were investigated for the analysis of TIGIT. Details of the overlapping patients and the number of the patients in each cancer cohort are listed in Supplementary Table 4 . FACS, fluorescence-activated cell sorting; TILs, tumor-infiltrating lymphocytes; PD-1, programmed cell death protein 1; Tim-3, T-cell immunoglobulin and mucin-domain containing-3; KLRG-1, killer cell lectin like receptor G1; 2B4, CD244; BTLA, B- and T-lymphocyte attenuator.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Higher frequencies of PD-1 and Tim-3 but lower frequencies of BTLA in T cells from tumors compared with peripheral blood in matched patient samples. Representative dot plots of eight inhibitory receptors on CD8 (A) and CD4 (B) TILs with FMO controls are shown. The exemplary plots are combined from two 8-color panels of two breast cancer patients. Full gating strategy of two 8-color panels and the 14-color panel is shown in Supplementary Figures 4 - 8 . FACS analysis of PD-1 (C,D) and Tim-3 (E,F) in CD8 (left) and CD4 (right) T cells was performed for 131 blood-tumor-matched primary cancer patients (see Figure 1 for details). Analysis of BTLA+ cells in CD8 (G) and CD4 (H) T cells was performed for 74 blood-tumor-matched cancer patients: 32 breast cancer, 10 liver cancer, 20 cervical cancer, and 12 digestive tract cancer (five esophageal cancer, four gastric cancer, and three colorectal cancer). Wilcoxon paired t -test was performed to detect the statistical significance ( * P < 0.0332, ** P < 0.0021, *** P < 0.0002, and **** P < 0.0001). The fraction of cells expressing PD-1, Tim-3, or BTLA on the surface of T cells in peripheral blood vs. tumor is shown as %. PD-1, programmed cell death protein 1; Tim-3, T-cell immunoglobulin, and mucin-domain containing-3; BTLA, B-, and T-lymphocyte attenuator; TILs, tumor-infiltrating lymphocytes; FMO, fluorescence minus one; FACS, fluorescence-activated cell sorting.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 Tim-3 and TIGIT are preferentially expressed on PD-1+ CD8 TILs across multiple types of cancer. Representative dot plots of the co-expression of PD-1 and Tim-3 on CD8 TILs (A) and the co-expression of PD-1 and TIGIT on CD8 TILs (B) from a breast cancer patient are shown. Data were collected utilizing the 14-color panel as mentioned above, with full gating strategy shown in Supplementary Figure 8 . (C) FACS analysis of the frequencies of Tim-3+PD-1-, PD-1+Tim-3-, and PD-1+Tim-3+ cells among CD8 TILs from 69 cancer patients (see Figure 3 for details). (D) FACS analysis of the frequencies of TIGIT+PD-1-, PD-1+TIGIT-, and PD-1+TIGIT+ cells among CD8 TILs from the same 69 cancer patients. Wilcoxon paired t -test was performed to detect the statistical significance ( * P < 0.0332, ** P < 0.0021, *** P < 0.0002, and **** P < 0.0001). Tim-3, T-cell immunoglobulin and mucin-domain containing-3; TIGIT, T-cell immunoglobulin and ITIM; TILs, tumor-infiltrating lymphocytes; PD-1, programmed cell death protein 1; FACS, fluorescence-activated cell sorting.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 6 Flow cytometry analysis of T cell-/lymphocyte-specific markers on normal and malignant B cells from CLL patients. a Summary scheme representing functional implications of CLL-specific candidate genes selected for flow cytometric analysis. b Flow cytometric analysis of expression of CTLA-4, TIGIT, CD276, LILRB4, and CD2 on peripheral blood B cells of CLL patients. The expression was determined for non-malignant B cells (""Normal""; CD19 + CD5 - B cells, represented in green) and neoplastic B cells (""CLL"", CD19 + CD5 + B cells, represented in orange) detected in the same samples. ""Co,"" no antibody staining control; ""Ab,"" staining with the antibody of interest as indicated. c Normalized median fluorescence intensities (target MFI - MFI of negative control [Co]; nMFI). d Delta normalized median fluorescence intensities between CLL cells and normal B cells (DeltanMFI (CLL-normal)) for each patient tested

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Changes in BM T cell function in children with B-ALL and AML at diagnosis. BMMNCs from B-ALL ( n = 13), AML ( n = 17), or HD ( n = 5) were cultured alone or with PMA/ionomycin in the presence of GolgiStop. After 4 hours of culture, cells were stained with dead cell exclusion dye as well as antibodies to detect surface CD3, CD4, CD8, PD-1, TIGIT, intracellular IFN-gamma, and IL-2 and analyzed using flow cytometry. ( A ) Proportion of CD8 + and CD4 + T cells secreting IFN-gamma and IL-2. ( B ) IFN-gamma secretion by cells expressing PD-1 and/or TIGIT. Figure shows a representative plot from patient with AML. All graphs show mean +- SEM. * P < 0.05 by Mann-Whitney U test with Bonferroni''s correction for multiple comparisons.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 Changes in BM T cell transcription factors in children with B-ALL and AML at diagnosis. BMMNCs from B-ALL ( n = 13), AML ( n = 17), or HD ( n = 5) were cultured alone or with PMA/ionomycin in the presence of GolgiStop. After 4 hours of culture, cells were stained with dead cell exclusion dye as well as antibodies to detect surface CD3, CD4, CD8, PD-1, TIGIT, intracellular IFN-gamma, and IL-2 and analyzed using flow cytometry. ( A ) Expression of TCF1, T-bet, GATA3, and EOMES transcription factors in memory CD4 + (left) and CD8 + (right) T cells in BMMNCs from HD and patients with B-ALL. ( B ) Expression of TCF1, T-bet, GATA3, and EOMES transcription factors in memory CD4 + (left) and CD8 + (right) T cells in BMMNCs from HD and patients with AML. ( C ) Tregs (CD3 + CD4 + CD25 + CD127 - FOXP3 hi ) as percentage of total T cells in BM from HD ( n = 11) and patients with B-ALL ( n = 36) and AML ( n = 28). ( D ) Heatmaps showing characteristics of the TCF1 hi and TCF1 - CD8 + memory T cells from HD, B-ALL, and AML. All graphs show mean +- SEM. ** P < 0.01, *** P < 0.001 by Mann-Whitney U test with Bonferroni''s correction for multiple comparisons.